GlassScriptPhysician profile
Tejinder Kalra
NPI 1629015011
$5,500.95
in general payments reported to CMS, 2019-2025
26 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,289 · 2020: $426 · 2021: $1,184 · 2022: $614 · 2023: $903 · 2024: $614 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,892 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,892.19 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,034.97 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $688.87 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $446.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $407.00 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $319.84 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $315.30 | 2019-2024 | Eliquis |
| Exact Sciences Corporation | $290.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $287.96 | 2020-2023 | Veozah |
| Abbvie INC. | $221.66 | 2022-2023 | |
| Horizon Therapeutics Plc | $213.12 | 2021-2022 | |
| Amgen INC. | $177.08 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $164.69 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.73 | 2019-2025 | Jascayd |
| Amarin Pharma, INC. | $128.90 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $109.44 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $80.06 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $75.98 | 2019-2021 | |
| Esperion Therapeutics, INC. | $75.85 | 2021-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $74.44 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $56.74 | 2023 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $43.42 | 2024 | Voquezna |
| Allergan, INC. | $33.60 | 2019 | |
| Verona Pharma, INC. | $28.00 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $27.18 | 2019-2020 | |
| Abbott Laboratories | $22.81 | 2023 | Freestyle Libre 3 |
| Shield Therapeutics INC | $21.48 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejinder Kalra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.